Pharmacokinetic comparison of different flubendazole formulations in pigs: A further contribution to its development as a macrofilaricide molecule

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 5, Issue 3, 2015, Pages 178-184

  Ceballos, L ^a   Alvarez, L ^a   Mackenzie, C ^b   Geary, T ^c   Lanusse, C ^a  

^a UNCPBA ^*  (Argentina)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Cyclodextrins; Flubendazole; Pharmaceutical preparations; Systemic exposure

Indexed keywords

ANTIFILARIAL AGENT; BETA CYCLODEXTRIN; CARBOXYMETHYLCELLULOSE; DRUG METABOLITE; FLUBENDAZOLE; POLYSORBATE 80; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTHELMINTIC AGENT; MEBENDAZOLE; POLYSORBATE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG STRUCTURE; FILARIASIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMISTRY; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG DOSAGE FORM; METABOLISM; ORAL DRUG ADMINISTRATION; PIG; SUBCUTANEOUS DRUG ADMINISTRATION; VETERINARY;

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ADMINISTRATION, ORAL; ANIMALS; ANTHELMINTICS; CARBOXYMETHYLCELLULOSE SODIUM; CROSS-OVER STUDIES; DOSAGE FORMS; INJECTIONS, SUBCUTANEOUS; MEBENDAZOLE; POLYSORBATES; SWINE;

EID: 84943795874     PISSN: None     EISSN: 22113207     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2015.09.001     Document Type: Article

References (31)

1. Alvarez L., Imperiale F., Sánchez S., Murno G., Lanusse C. Uptake of albendazole and albendazole sulphoxide by Haemonchus contortus and Fasciola hepatica in sheep. Vet. Parasitol. 2000, 94:75-89.
2. Alvarez L., Moreno G., Moreno L., Ceballos L., Shaw L., Fairweather I., Lanusse C. Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs. Vet. Parasitol. 2009, 164:211-216.
3. Awadzi K. Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J. 2003, 2(Suppl. 1):S6.
4. Basáñez M., Pion S.D., Boakes E., Filipe J.A., Churcher T.S., Boussinesq M. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect. Dis. 2008, 8(5):310-322.
5. Bird A., El-Sheikh H., Anderson J., Fuglsang H. Visual loss during oral diethylcarbamazine treatment for onchocerciasis. Lancet 1979, 2:8132-8146.
6. Ceballos L., Elissondo M., Bruni S., Denegri G., Alvarez L., Lanusse C. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol. Int. 2009, 58:354-358.
7. Ceballos L., Elissondo C., Sanchez Bruni S., Denegri G., Lanusse C., Alvarez L. Comparative performance of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma/cysts disposition and efficacy in infected mice. Antimicrob. Agents Chemother. 2011, 55:5861-5867.
8. Ceballos L., Moreno L., Torrado J., Lanusse C., Alvarez L. Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution. BMC Vet. Res. 2012, 8(1):71.
9. Ceballos L., Mackenzie C., Geary T., Alvarez L., Lanusse C. Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations. PLoS Negl. Trop. Dis. 2014, 10.1371/journal.pntd.0002838.
10. Dalgaard L. Comparison of minipig, dog, monkey and human drug metabolism and disposition. J. Pharmacol.Toxicol. Methods. 2015, 10.1016/j.vascn.2014.12.005.
11. EMEA The European Agency for the Evaluation of Medicinal Products. Flubendazol 1997, EMEA/MRL/267/97-FINAL, Summary Report 2, Veterinary Medicines Evaluation Unit, Committee for Veterinary Medicinal Products, London, UK. http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014288.pdf.
12. Evrard B., Chiap P., DeTullio F., Ghalmid F., Piela G., Van Heesa T., Crommen J., Losson B., Delattre L. Oral bioavailability in sheep of albendazole from a suspension on and from a solution containing hydroxypropyl-β-cyclodextrin. J. Control Release 2002, 85:45-50.
13. Garcia J., Bolas F., Torrado J. Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int. J. Pharm. 2003, 250:351-358.
14. Geary T., Woo K., McCarthy J., Mackenzie C., Horton J., Prichard R., de Silva N., Olliaro P., Lazdins-Helds J., Engels D., Bundy D. Unresolved issues in anthelmintic pharmacology for helminthiases of humans. Int. J. Parasitol. 2010, 40:1-13.
15. Gibaldi M., Perrier D. Pharmacokinetics 1982, 45-109. Revised and Expanded. New York, Marcel Dekker, USA. second ed.
16. Hennessy D., Al i D., Sillince J. The effect of a short-term reduction in feed on the pharmacokinetics and efficacy of albendazole in sheep. Aust. Vet. J. 1995, 72:29-30.
17. Lanusse C., Gascon L., Prichard R. Comparative plasma disposition kinetics of albendazole, fenbendazole, oxfendazole and their metabolites in adult sheep. J. Vet. Pharmacol. Ther. 1995, 18:196-203.
18. Lloberas M., Alvarez L., Entrocasso C., Virkel G., Lanusse C., Lifschitz A. Measurement of ivermectin concentrations in target worms and host gastrointestinal tissues: influence of the route of administration on the activity against resistant Haemonchus contortus in lambs. Exp. Parasitol. 2012, 10.1016/j.exppara.2012.04.014.
19. Loftsson T., Duchene D. Historical Perspectives. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329:1-11.
20. Mackenzie C., Geary T. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert. Rev. Anti. Infect Ther. 2011, 9:497-501.
21. Maté L., Virkel G., Lifschitz A., Ballent M., Lanusse C. Hepatic and extra-hepatic metabolic pathways involved in flubendazole biotransformation in sheep. Biochem. Pharmacol. 2008, 76:773-783.
22. Moreno L., Alvarez L., Mottier L., Virkel G., Sanchez Bruni S., Lanusse C. Integrated pharmacological assessment of flubendazole potential for use in sheep: disposition kinetics, liver metabolism and parasite difussion ability. J. Vet. Pharmacol. Ther. 2004, 27:299-308.
23. Muller R.H., Schmidt S., Buttle I., Akkar A., Schmitt J., Bromer S. SolEmuls(R)-novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int. J. Pharm. 2004, 269:293-302.
24. Rigter I., Schipper H., Koopmans R., van Kan H., Frijlink H., Kager P., Guchelaar H. Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Antimicrob. Agents Chemother. 2004, 48:1051-1054.
25. Suarez G., Alvarez L., Castells D., Correa O., Fagiolino P., Lanusse C. Comparative drug systemic exposure and clinical efficacy against resistant nematodes in lambs treated with different albendazole formulations. J. Vet. Pharmacol. Ther. 2011, 34:557-564.
26. Taylor M., Hoerauf A., Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet 2010, 376:1175-1185.
27. Toutain P., Bousquet-Mélou A. Bioavailability and its assessment. J. Vet. Pharmacol. Ther. 2004, 27:455-466.
28. Urbizu L., Confalonieri A., Sanchez Bruni S., Lanusse C., Alvarez L. Nematodicidal activity of flubendazole and its reduced metabolite on a murine model of Trichinella spiralis infection. Chemotherapy 2012, 58:295-298.
29. WHO Programmes Available at:. http://www.who.int/apoc/onchocerciasis/status/en/.
30. Wu Z., Tucker I., Razzak M., Yang L., McSporran K., Medlicott N. Absorption and tissue tolerance of ricobendazole in the presence of hydroxypropyl-β-cyclodextrin following subcutaneous injection in sheep. Int. J. Pharm. 2010, 397:96-102.
31. Zahner H., Schares G. Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi. Acta Trop. 1993, 52:221-266.